Nebulizer systems: a new frontier for therapeutics and targeted delivery

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Singh A, Malviya R, Sharma PK. Pulmonary drug delivery system: a novel approach for drug delivery. Curr. Drug Ther. 6(2), 137–151 (2011).
  CASGoogle Scholar
• 2. Labiris NR, Dolovich MB. Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br. J. Clin. Pharmacol. 56(6), 588–599 (2003). •• A useful review highlighting critical factors to consider when developing aerosolized medications.
  Medline CASGoogle Scholar
• 3. Hickey AJ. Emerging trends in inhaled drug delivery. Adv. Drug Deliv. Rev. 157, 63–70 (2020).
  Medline CASGoogle Scholar
• 4. Labiris NR, Dolovich MB. Pulmonary drug delivery. Part II: the role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications. Br. J. Clin. Pharmacol. 56(6), 600–612 (2003). •• Sheds light on the important factors that influence the type of aerosol delivery system and drug formulation on a drug's therapeutic effectiveness.
  Medline CASGoogle Scholar
• 5. Christie T. On inhaling the smoke of datura in asthma. Edinb. Med. Surg. J. 7(26), 158–160 (1811).
  MedlineGoogle Scholar
• 6. Yıldız-Peköz A, Ehrhardt C. Advances in pulmonary drug delivery. Pharmaceutics 12(10), 911 (2020).
  Google Scholar
• 7. Javadzadeh Y, Yaqoubi S. Therapeutic nanostructures for pulmonary drug delivery. In: Nanostructures for Drug Delivery. Andronescu EGrumezescu AM (Eds). 619–638 Elsevier Inc, Amsterdam, Netherlands (2017).
  Google Scholar
• 8. Groneberg DA, Witt C, Wagner U, Chung KF, Fischer A. Fundamentals of pulmonary drug delivery. Respir. Med. 97(4), 382–387 (2003).
  Medline CASGoogle Scholar
• 9. Patton JS, Byron PR. Inhaling medicines: delivering drugs to the body through the lungs. Nat. Rev. Drug Discov. 6(1), 67–74 (2007).
  Medline CASGoogle Scholar
• 10. Hock SC, Ying YM, Wah CL. A review of the current scientific and regulatory status of nanomedicines and the challenges ahead. PDA J. Pharm. Sci. Technol. 65(2), 177–195 (2011).
  Medline CASGoogle Scholar
• 11. Newman SP. Drug delivery to the lungs: challenges and opportunities. Ther. Deliv. 8(8), 647–661 (2017).
  CASGoogle Scholar
• 12. Pritchard JN. Nebulized drug delivery in respiratory medicine: what does the future hold? Ther. Deliv. 8(6), 391–399 (2017).
  CASGoogle Scholar
• 13. Thorat S, Meshram S. Formulation and product development of pressurised metered dose inhaler: an overview. PharmaTutor 3(9), 53–64 (2015).
  CASGoogle Scholar
• 14. Kwok PCL, Chan HK. Pulmonary drug delivery. Ther. Deliv. 4(8), 877–878 (2013).
  CASGoogle Scholar
• 15. Le Brun PPH, De Boer AH, Frijlink HW, Heijerman HGM. A review of the technical aspects of drug nebulization. Pharm. World Sci. 22(3), 75–81 (2000). • Review presents the technical features of the nebulization of drug solutions.
  MedlineGoogle Scholar
• 16. Geller DE. Comparing clinical features of the nebulizer, metered-dose inhaler, and dry powder inhaler. Respir. Care. 50(10), 1313–1322 (2005).
  MedlineGoogle Scholar
• 17. Pirozynski M, Sosnowski TR. Inhalation devices: from basic science to practical use, innovative vs generic products. Expert Opin. Drug Deliv. 13(11), 1559–1571 (2016).
  Medline CASGoogle Scholar
• 18. Djupesland PG. Nasal drug delivery devices: characteristics and performance in a clinical perspective—a review. Drug Deliv. Transl. Res. 3(1), 42–62 (2013).
  Medline CASGoogle Scholar
• 19. Cho H-S, Wan G-H, Hsieh M-J. Performance of different types of nebulizer with spontaneous adult breathing pattern. Presented at: American Thoracic Society 2016 International Conference. San Francisco, CA, USA (2016).
  Google Scholar
• 20. Pilcer G, Amighi K. Formulation strategy and use of excipients in pulmonary drug delivery. Int. J. Pharm. 392(1–2), 1–19 (2010).
  Medline CASGoogle Scholar
• 21. Ibrahim M, Verma R, Garcia-Contreras L. Inhalation drug delivery devices: technology update. Med. Devices (Auckl). 8, 131–139 (2015).
  Medline CASGoogle Scholar
• 22. Dolovich MB, Dhand R. Aerosol drug delivery: developments in device design and clinical use. Lancet 377(9770), 1032–1045 (2011). • Focuses on the significant advances in the design and clinical application of aerosol devices.
  Medline CASGoogle Scholar
• 23. Ari A. Jet, ultrasonic, and mesh nebulizers: an evaluation of nebulizers for better clinical outcomes. Eurasian J. Pulmonol. 16, 1–7 (2014).
  Google Scholar
• 24. Elphick M, Hollen DV, Pritchard JN, Nikander K, Hardaker LEA, Hatley RHM. Factors to consider when selecting a nebulizer for a new inhaled drug product development program. Expert Opin. Drug Deliv. 12(8), 1375–1387 (2015). •• Summarizes the different types of nebulizer technologies and discusses the factors to be considered when selecting a technology for a new inhaled drug.
  Medline CASGoogle Scholar
• 25. Page CP, Barnes PJ. In: Pharmacology and Therapeutics of Asthma and COPD. Springer, NY, USA (2017).
  Google Scholar
• 26. Sethi S, Barjaktarevic IZ, Tashkin DP. The use of nebulized pharmacotherapies during the COVID-19 pandemic. Ther. Adv. Respir. Dis. 14, 1753466620954366 (2020).
  Google Scholar
• 27. Respaud R, Vecellio L, Diot P, Heuzé-Vourc'h N. Nebulization as a delivery method for mAbs in respiratory diseases. Expert Opin Drug Deliv. 12(6), 1027–1039 (2015).
  Medline CASGoogle Scholar
• 28. Pritchard JN, Hatley RH, Denyer J, Hollen DV. Mesh nebulizers have become the first choice for new nebulized pharmaceutical drug developments. Ther. Deliv. 9(2), 121–136 (2018).
  CASGoogle Scholar
• 29. Tashkin DP. A review of nebulized drug delivery in COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 11, 2585–2596 (2016).
  Medline CASGoogle Scholar
• 30. Prajapati S, Saha S, Sahoo B. Nebulized drug delivery: an overview. Int. J. Pharm. Sci. Res. 10(8), 3575–3582 (2019).
  CASGoogle Scholar
• 31. Newman SP. Delivering drugs to the lungs: the history of repurposing in the treatment of respiratory diseases. Adv. Drug Deliv. Rev. 133, 5–18 (2018).
  Medline CASGoogle Scholar
• 32. Dhand R. Intelligent nebulizers in the age of the internet: the I-neb Adaptive Aerosol Delivery (AAD) System. J. Aerosol Med. Pulm. Drug Deliv. 23(Suppl. 1), iii–v (2010).
  MedlineGoogle Scholar
• 33. Geller DE. The science of aerosol delivery in cystic fibrosis. Pediatr. Pulmonol. 43(S9), S5–S17 (2008).
  Google Scholar
• 34. Weber A, Morlin G, Cohen M, Williams-Warren J, Ramsey B, Smith A. Effect of nebulizer type and antibiotic concentration on device performance. Pediatr. Pulmonol. 23(4), 249–260 (1997).
  Medline CASGoogle Scholar
• 35. Eschenbacher WL, Boushey HA, Sheppard D. Alteration in osmolarity of inhaled aerosols cause bronchoconstriction and cough, but absence of a permeant anion causes cough alone. Am. Rev. Respir. Dis. 129(2), 211–215 (1984).
  Medline CASGoogle Scholar
• 36. Beasley R, Fishwick D, Miles JF, Hendeles L. Preservatives in nebulizer solutions: risks without benefit. Pharmacotherapy 18(1), 130–139 (1998).
  Medline CASGoogle Scholar
• 37. Poulakou G, Siakallis G, Tsiodras S, Arfaras-Melainis A, Dimopoulos G. Nebulized antibiotics in mechanically ventilated patients: roadmap and challenges. Expert Rev. Anti Infect. Ther. 15(3), 211–229 (2017).
  Medline CASGoogle Scholar
• 38. Fonceca AM, Fox Ditcham WG, Everard ML, Devadason S. 16 - Drug Administration by Inhalation in Children. In: Kendig's Disorders of the Respiratory Tract in Children. Wilmot RDeterding RLi A et al. Eds). 257–271 Elsevier Inc, Amsterdam, Netherlands (2019).
  Google Scholar
• 39. Dunbar C, Mitchell J. Analysis of cascade impactor mass distributions. J. Aerosol Med. 18(4), 439–451 (2005).
  Medline CASGoogle Scholar
• 40. Mitchell J, Newman S, Chan H-K. In vitro and in vivo aspects of cascade impactor tests and inhaler performance: a review. AAPS PharmSciTech. 8(4), 237–248 (2007).
  Google Scholar
• 41. Mitchell JP, Nagel MW. Cascade impactors for the size characterization of aerosols from medical inhalers: their uses and limitations. J. Aerosol Med. 16(4), 341–377 (2003).
  Medline CASGoogle Scholar
• 42. Martin AR, Finlay WH. Nebulizers for drug delivery to the lungs. Expert Opin. Drug Deliv. 12(6), 889–900 (2015). • This review features in vivo, in vitro and ex vivo models currently available for studying lung absorption and disposition and several challenges associated with these techniques.
  Medline CASGoogle Scholar
• 43. Sakagami M. In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery. Adv. Drug Deliv. Rev. 58(9–10), 1030–1060 (2006).
  Medline CASGoogle Scholar
• 44. Cobben NAM, Drent M, Jonkers M, Wouters EFM, Vaneechoutte M, Stobberingh EE. Outbreak of severe Pseudomonas aeruginosa respiratory infections due to contaminated nebulizers. J. Hosp. Infect. 33(1), 63–70 (1996).
  Medline CASGoogle Scholar
• 45. Amirav I, Newhouse MT. Transmission of coronavirus by nebulizer: a serious, underappreciated risk. CMAJ 192(13), E346–E346 (2020).
  Medline CASGoogle Scholar
• 46. Le Brun P, Brimicombe R, Van Doorne H, Heijerman H. The cleaning and disinfection of nebulizers used at home and in a cystic fibrosis centre. Eur. Hosp. Pharm. 6(2), 58–63 (2000). • Summarizes the advancement in nebulizer drug delivery and discusses its application in treatment of various respiratory ailments.
  Google Scholar
• 47. Li Q, Zhan S, Liu Q et al. Preparation of a sustained-release nebulized aerosol of r-terbutaline hydrochloride liposome and evaluation of its anti-asthmatic effects via pulmonary delivery in guinea pigs. AAPS PharmSciTech. 19(1), 232–241 (2018).
  Medline CASGoogle Scholar
• 48. Zhang J, Liang X, Li X et al. Ocular delivery of cyanidin-3-glycoside in liposomes and its prevention of selenite-induced oxidative stress. Drug Dev. Ind. Pharm. 42(4), 546–553 (2016).
  Medline CASGoogle Scholar
• 49. Cipolla D, Blanchard J, Gonda I. Development of liposomal ciprofloxacin to treat lung infections. Pharmaceutics. 8(1), 6 (2016).
  Google Scholar
• 50. Godet C, Cateau E, Rammaert B et al. Nebulized liposomal amphotericin B for treatment of pulmonary infection caused by hormographiella aspergillata: case report and literature review. Mycopathologia 182(7), 709–713 (2017).
  Medline CASGoogle Scholar
• 51. Tagami T, Ando Y, Ozeki T. Fabrication of liposomal doxorubicin exhibiting ultrasensitivity against phospholipase A2 for efficient pulmonary drug delivery to lung cancers. Int. J. Pharm. 517(1), 35–41 (2017).
  Medline CASGoogle Scholar
• 52. Subramanian S, Khan I, Korale O et al. A simple approach to predict the stability of phospholipid vesicles to nebulization without performing aerosolization studies. Int. J. Pharm. 502(1), 18–27 (2016).
  Medline CASGoogle Scholar
• 53. Tai T-T, Wu T-J, Wu H-D et al. A strategy to treat COVID-19 disease with targeted delivery of inhalable liposomal hydroxychloroquine: a preclinical pharmacokinetic study. Clin. Transl. Sci. 14(1), 132–136 (2021).
  Medline CASGoogle Scholar
• 54. Schreier H, Gonzalez-Rothi RJ, Stecenko AA. Pulmonary delivery of liposomes. J. Control. Rel. 24(1–3), 209–223 (1993).
  CASGoogle Scholar
• 55. Makled S, Nafee N, Boraie N. Nebulized solid lipid nanoparticles for the potential treatment of pulmonary hypertension via targeted delivery of phosphodiesterase-5-inhibitor. Int. J. Pharm. 517(1), 312–321 (2017).
  Medline CASGoogle Scholar
• 56. Jansook P, Fülöp Z, Ritthidej GC. Amphotericin B loaded solid lipid nanoparticles (SLNs) and nanostructured lipid carrier (NLCs): physicochemical and solid-solution state characterizations. Drug Dev. Ind. Pharm. 45(4), 560–567 (2019).
  Medline CASGoogle Scholar
• 57. Arora R, Katiyar SS, Kushwah V, Jain S. Solid lipid nanoparticles and nanostructured lipid carrier-based nanotherapeutics in treatment of psoriasis: a comparative study. Expert Opin. Drug Deliv. 14(2), 165–177 (2017).
  Medline CASGoogle Scholar
• 58. Yue-Xing C, Fei-Fei Y, Han W et al. The effect of l-leucine on the stabilization and inhalability of spray-dried solid lipid nanoparticles for pulmonary drug delivery. J. Drug Deliv. Sci. Technol. 46, 474–481 (2018).
  Google Scholar
• 59. Esmaeili M, Aghajani M, Abbasalipourkabir R, Amani A. Budesonide-loaded solid lipid nanoparticles for pulmonary delivery: preparation, optimization, and aerodynamic behavior. Artif. Cells Nanomed. Biotechnol. 44(8), 1964–1971 (2016).
  Medline CASGoogle Scholar
• 60. Buhecha MD, Lansley AB, Somavarapu S, Pannala AS. Development and characterization of PLA nanoparticles for pulmonary drug delivery: co-encapsulation of theophylline and budesonide, a hydrophilic and lipophilic drug. J. Drug Deliv. Sci. Technol. 53, 101128 (2019).
  CASGoogle Scholar
• 61. Al Malyan M, Becchi C, Nikkola L et al. Polymer-based biodegradable drug delivery systems in pain management. J. Craniofac. Surg. 17(2), 302–13 (2006).
  MedlineGoogle Scholar
• 62. Moreno-Sastre M, Pastor M, Salomon CJ, Esquisabel A, Pedraz JL. Pulmonary drug delivery: a review on nanocarriers for antibacterial chemotherapy. J. Antimicrob. Chemother. 70(11), 2945–2955 (2015).
  Medline CASGoogle Scholar
• 63. Doroudian M, Macloughlin R, Poynton F, Prina-Mello A, Donnelly SC. Nanotechnology based therapeutics for lung disease. Thorax 74(10), 965–976 (2019).
  MedlineGoogle Scholar
• 64. Rogueda PGA, Traini D. The nanoscale in pulmonary delivery. Part 2: formulation platforms. Expert Opin. Drug Deliv. 4(6), 607–620 (2007).
  Medline CASGoogle Scholar
• 65. Joshi N, Shirsath N, Singh A, Joshi KS, Banerjee R. Endogenous lung surfactant inspired pH responsive nanovesicle aerosols: pulmonary compatible and site-specific drug delivery in lung metastases. Sci. Rep. 4(1), 7085 (2014).
  MedlineGoogle Scholar
• 66. Kumar A, Chen F, Mozhi A et al. Innovative pharmaceutical development based on unique properties of nanoscale delivery formulation. Nanoscale 5(18), 8307–8325 (2013).
  Medline CASGoogle Scholar
• 67. Van Rijt SH, Bein T, Meiners S. Medical nanoparticles for next generation drug delivery to the lungs. Eur. Respi. J. 44(3), 765 (2014).
  Medline CASGoogle Scholar
• 68. Kaminskas LM, Mcleod VM, Ryan GM et al. Pulmonary administration of a doxorubicin-conjugated dendrimer enhances drug exposure to lung metastases and improves cancer therapy. J. Control. Rel. 183, 18–26 (2014).
  Medline CASGoogle Scholar
• 69. Bailey MM, Berkland CJ. Nanoparticle formulations in pulmonary drug delivery. 29(1), 196–212 (2009).
  Google Scholar
• 70. Rutsaert L, Steinfort N, Van Hunsel T et al. COVID-19-associated invasive pulmonary aspergillosis. Ann. Intensive Care 10, 1–4 (2020).
  MedlineGoogle Scholar
• 71. Kaur R, Dennison SR, Burrow AJ et al. Nebulised surface-active hybrid nanoparticles of voriconazole for pulmonary Aspergillosis demonstrate clathrin-mediated cellular uptake, improved antifungal efficacy and lung retention. J. Nanobiotechnol. 19(1), 19 (2021).
  Medline CASGoogle Scholar
• 72. Zachar O. Formulations for COVID-19 early stage treatment via silver nanoparticles inhalation delivery at home and hospital. ScienceOpen Preprints (2020).
  Google Scholar
• 73. Weber S, Zimmer A, Pardeike J. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for pulmonary application: a review of the state of the art. Eur. J. Pharm. Biopharm. 86(1), 7–22 (2014).
  Medline CASGoogle Scholar
• 74. Zhang L, Yang L, Zhang X et al. Sustained therapeutic efficacy of budesonide-loaded chitosan swellable microparticles after lung delivery: influence of in vitro release, treatment interval and dose. J. Control. Rel. 283, 163–174 (2018).
  Medline CASGoogle Scholar
• 75. Amore E, Ferraro M, Manca ML et al. Mucoadhesive solid lipid microparticles for controlled release of a corticosteroid in the chronic obstructive pulmonary disease treatment. Nanomedicine 12(19), 2287–2302 (2017).
  Medline CASGoogle Scholar
• 76. Chen Y, Du S, Zhang Z et al. Compatible stability and aerosol characteristics of Atrovent^® (Ipratropium Bromide) mixed with salbutamol sulfate, terbutaline sulfate, budesonide, and acetylcysteine. 12(8), 776 (2020).
  Google Scholar
• 77. Yarragudi SB, Kumar H, Jain R, Tawhai M, Rizwan S. Olfactory targeting of microparticles through inhalation and bi-directional airflow: effect of particle size and nasal anatomy. J. Aerosol Med. Pulm. Drug Deliv. 33(5), 258–270 (2020).
  Medline CASGoogle Scholar
• 78. Pulivendala G, Bale S, Godugu C. Inhalation of sustained release microparticles for the targeted treatment of respiratory diseases. Drug Deliv. Transl. Res. 10(2), 339–353 (2020).
  Medline CASGoogle Scholar
• 79. Ali ZA, El-Mallakh RS. Nebulized lidocaine in COVID-19, an hypothesis. Med. Hypotheses 144, 109947 (2020).
  Medline CASGoogle Scholar
• 80. Chaccour C, Abizanda G, Irigoyen-Barrio Á et al. Nebulized ivermectin for COVID-19 and other respiratory diseases, a proof of concept, dose-ranging study in rats. Sci. Rep. 10(1), 17073 (2020).
  Medline CASGoogle Scholar
• 81. Lin Y-R, Wu F-Y, Xiao H et al. Mycobacterium vaccae nebulization in the treatment of COVID-19: a randomized, double-blind, placebo-controlled trial. J. Aerosol. Med. Pulm. Drug Deliv. 34(2), 108–114 (2021).
  Medline CASGoogle Scholar